Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

This suggests that GLP-1 receptor agonists may offer a ... are needed to fully understand their efficacy and mechanisms of action in humans. Glucagon-like peptide-1 (GLP-1): A hormone that helps ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

“Glucagon-Like Peptide-1 Receptor: Mechanisms and Advances in Therapy.” Signal Transduction Targeted Ther. (Sept. 2024). DOI: 10.1038/s41392-024-01931-z. A collaboration between C&EN and Andy ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...